Why the study?
Do stents reduce mortality compared to balloon angioplasty in patients with non-acute coronary artery disease?
Do stents reduce mortality compared to balloon angioplasty in patients with non-acute coronary artery disease?
In non-acute coronary disease, stents reduce target vessel revascularization but increase bleeding risk compared to balloon angioplasty, with a potential mortality benefit when used with glycoprotein IIb/IIIa inhibitors.
Stents may reduce mortality and revascularizations versus balloon angioplasty in non-acute CAD; extends meta-analytic evidence but needs contemporary confirmation given borderline mortality signal.
AIMS: To evaluate whether stents as compared to balloon angioplasty reduce mortality in patients with non-acute coronary artery disease. METHODS AND RESULTS: We identified randomized controlled trials comparing stents to balloon angioplasty for the treatment of non-acute coronary artery disease by searching major medical databases from 1979 to March 2002. Two independent reviewers selected and extracted data from trials that had to report data on death and myocardial infarction. Nineteen trials, with a total of 8004 patients, fulfilled our inclusion criteria. For 1000 patients treated with stents rather than balloon angioplasty, 3 (95% CI 0-6), 5 (95% CI 0-9), and 6 (95% CI -1-12) additional lives were saved at 30 days, 6 and 12 months. At 12 months, for 1000 patients treated with stents rather than balloon angioplasty 46 (95% CI 25-66) additional target vessel revascularizations were avoided, but 25 (95% CI 15-34) additional bleeding complications with need for blood transfusion or surgical intervention occurred. In sensitivity analysis 11 (95% CI 2-20) and 2 (95% CI -4-7) deaths were avoided per 1000 patients treated with stents rather than PTCA in trials that routinely used compared to trials that did not use glycoprotein IIb/IIIa inhibitors. CONCLUSION: In non-acute coronary disease stents may reduce overall mortality, but this benefit seems to be limited to stents used in conjunction with glycoprotein IIb/IIIa inhibitors. Stents compared to PTCA reduce target vessel revascularizations, but increase the risk of bleeding complications.
No takes yet. Share an insight, caveat, or question.
Alain Nordmann (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: